/PRNewswire/ Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the.
STOCKHOLM, April 30, 2024 /PRNewswire/ — Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to […]
The Nomination Committee s in Medivir AB proposal for the 2024 annual general meeting In accordance with the principles decided by the 2023 annual general.
/PRNewswire/ "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6.
/PRNewswire/ Medivir AB (Nasdaq Stockholm: MVIR) ("Medivir" or the "Company"), a pharmaceutical company focused on developing innovative treatments for.